Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

FIT Hon Teng IPO Early Thought: Parent Hon Hai Has a Different Focus

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/22868" target="_blank" data-smartkarma-citation="entities:22868:1">FIT Hon Teng (6088 HK)</a> relaunched its IPO to raise up to US$393m after its previous IPO was pulled in 2016. We have covered the fundamental aspects of the company previously (<a href="https://www.smartkarma.com/insights/fit-hon-teng-ipo-early-thought-parent-hon-hai-has-a-different-focus" target="_blank">link</a> to previous insight). In this insight, we will look at changes since its previous listing attempt, and score the deal in our ECM framework. </p><div><h2>Deal and framework score overview</h2></div><p>Regular readers will be familiar with the below embed from our IPO tool which has been designed to provide you with timely information on all IPO…</p>

FIT Hon Teng (6088 HK) relaunched its IPO to raise up to US$393m after its previous IPO was pulled in 2016. We have covered the fundamental aspects of the company previously (link to previous insight). In this insight, we will look at changes since its previous listing attempt, and score the deal in our ECM framework. Deal and framework score overviewRegular readers will be familiar with the below embed from our IPO tool which has been designed to provide you with timely information on all IPO…

FIT Hon Teng: IPO Relaunched, What's New and So What?